Andrea Ponti

GHO Capital Partners LLP (GHO Capital Partners) is a private equity firm founded in 2014 by Mireille G. Gillings, Dennis B. Gillings, Alan Browning MacKay, Michael Irvine Mortimer and Andrea Ponti. The firm is headquartered in London, United Kingdom.

Caprion Proteomics, Inc. provides proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. It specializes in proteomics, biomarkers, discovery, validation, services, immune monitoring, flow cytometry and elispot areas. The company was founded by Neil Cashman and Martin LeBlanc in 2000 and is headquartered in Montreal, Canada.

Part of GHO Capital Partners LLP, Iris Topco (UK) Ltd. is a holding British company that distributes pharmaceutical goods and medical devices. The company is based in London, UK and was founded in 2016.

Part of GHO Capital Partners LLP, GHO Capital Ltd. functions as an investment holding British company. The company is based in London, UK. It was founded in 2013.

Part of Envision Pharma, Inc., Envision Pharma Bidco Ltd. functions as an investment holding British company. The company is based in Horsham, UK and was founded in 2016.

Founded in 2016, Envision Pharma Midco Ltd. is a British company that functions as an investment holding company. Part of Envision Pharma, Inc., the company is based in Horsham, UK.

Part of Envision Pharma, Inc., Envision Pharma Trustee Ltd. is a British company that provides professional, scientific and technical activities. The company is based in Horsham, UK and was founded in 2016.

Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA.

Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022.